Atlas Venture
http://www.atlasventure.com/Atlas Venture is a venture capital firm that invests in early stage technology and life sciences businesses. Since the firm’s founding in 1980, the firm has helped build over three hundred companies. Since 1995, forty seven of its investments have been acquired and more than forty have gone public, with an aggregate market capitalization of over $20 billion.
View Older Stories View More Recent Stories
-
Rodin Therapeutics Advances Synaptic Resilience Strategy with $27 Million in Financing and Expands Board of Directors
-
Replimune Raises $55 Million to Advance its Oncolytic Immunotherapy Programs
-
Form 3 SYNLOGIC, INC. For: Aug 28 Filed by: Atlas Venture Fund IX, L.P.
-
Synlogic Completes Merger with Mirna Therapeutics
-
The Trout Group and The Conference Forum Announce Immuno-Oncology 360° Partnership to Fight a Wider Range of Cancers
-
Bristol-Myers Squibb (BMY) to Acquire IFM Therapeutics
-
Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity
-
Form 13F-HR Atlas Venture Associates For: Jun 30
-
Form 4 Intellia Therapeutics, For: Jul 07 Filed by: Atlas Venture Fund IX, L.P.
-
Form D Atlas Venture Fund XI,
-
Atlas Venture Announces $350 Million Fund XI
-
Xtera(R) Chairman and Chief Strategy Officer to Serve as Programme Chair for SubOptic 2019
-
Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts
-
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology
-
Atlas Venture Names Kevin Bitterman as New Partner
-
Bicycle Therapeutics Closes £40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline
-
Bicycle Therapeutics Closes £40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline
-
Scholar Rock Announces Drug Development Leaders, Michael Gilman and Shelia Violette, to Join Scientific Advisory Board
-
IFM Therapeutics Appoints H. Martin Seidel as Executive Vice President of Research and Development
-
Mirna Therapeutics (MIRN) to Merger with Synlogic
-
Synlogic and Mirna Therapeutics Agree to Merger
-
Form 13F-HR Atlas Venture Associates For: Mar 31
-
Industry Veteran Peter Barrett To Lead Harvard Business School's Blavatnik Fellowship in Life Science Entrepreneurship
-
Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting
-
Magenta Therapeutics Advances Stem Cell Transplantation Strategy with $50 Million Series B Financing, Licensing of Clinical-Stage Stem Cell Expansion Program and Strategic Partnership with Be The Matc
-
Be The Match BioTherapies Announces Collaboration Agreement with Magenta Therapeutics
-
JDA Expands Leadership Team
-
SaltDNA and Equiis Technologies Switzerland AG Announce Strategic Technology Partnership
-
Synlogic to Present at 2017 American College of Medical Genetics and Genomics Annual Meeting
-
Square 1 Bank Announces Credit Facility to Unum Therapeutics
-
Form 4 Intellia Therapeutics, For: Mar 09 Filed by: Atlas Venture Associates IX, L.P.
-
Spero Therapeutics Secures $51.7 Million in Oversubscribed Series C Financing
-
Form 4 Intellia Therapeutics, For: Mar 03 Filed by: Atlas Venture Fund IX, L.P.
-
Form SC 13D MIRAGEN THERAPEUTICS, Filed by: Atlas Venture Fund VII L P
-
IFM Therapeutics Appoints Renowned Physicians from Academia and Industry to Clinical Advisory Board
-
SaltDNA Combines Privacy, Control and Compliance for MiFID II in Latest Enterprise Release
-
Form 3 MIRAGEN THERAPEUTICS, For: Feb 13 Filed by: Atlas Venture Fund VII L P
-
miRagen Therapeutics (MGEN) Completes Merger with Signal Genetics (SGNL)
-
miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing
-
Form 13F-HR Atlas Venture Associates For: Dec 31
-
Form SC 13G/A Egalet Corp Filed by: Atlas Venture Fund VII L P
-
Form SC 13G/A ZAFGEN, INC. Filed by: Atlas Venture Fund VII L P
-
Form SC 13G Intellia Therapeutics, Filed by: Atlas Venture Fund IX, L.P.
-
Surface Oncology Appoints Jeff Goater as Chief Business Officer
-
Celgene (CELG) Announces Agreement to Acquire Delinia
-
Celgene to Acquire Delinia, Inc.
-
Allergan (AGN) Says It Purchased an Exclusive Option Right to Acquire LTI
-
Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds
-
Surface Oncology Welcomes Industry Leader Daniel S. Lynch as Chairman of Board of Directors
-
Harbour BioMed Acquires Harbour Antibodies to Create Global, Oncology-focused Biotechnology Company

